Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 3/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644787 | 0.78 | POLB (0.49) | ALDH1A1CYP1A2HTR6HTR3EHTR3B | |
| SCHEMBL30631698 | 0.75 | ALDH1A1 (0.58) | MAPTALDH1A1HTTMEN1KMT2A | |
| SCHEMBL2234081 | 0.74 | ADRA2C (0.52) | MAPTALDH1A1HTTL3MBTL1CYP1A2 | |
| SCHEMBL4147985 | 0.74 | ADRB1 (0.32) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL5536482 | 0.74 | CTSS (0.44) | MAPTALDH1A1HTR1DHTR2CHTR3E | |
| SCHEMBL6626303 | 0.72 | POLB (0.44) | ALDH1A1CYP3A4CYP2C19HTR6HRH3 | |
| SCHEMBL6151619 | 0.69 | ADRB1 (0.61) | MAPTALDH1A1HTTL3MBTL1HTR6 | |
| SCHEMBL12832086 | 0.69 | ADRB1 (0.61) | MAPTALDH1A1HTTL3MBTL1HTR6 | |
| Piperazine SCHEMBL28708983 | 0.69 | ADRB1 (0.61) | MAPTALDH1A1HTTL3MBTL1HTR6 | |
| SCHEMBL6782990 | 0.67 | KDM4E (0.41) | MAPTALDH1A1HTTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911457-B2 | Imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions. | CARBOMER, INC. (US) | 2005-06-28 | — | — | US | claimed |
| US-20030207823-A1 | Novel diabetes imaging probes | CARBOMER, INC. | 2003-11-06 | — | — | US | claimed |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| EP-2433963-A1 | Receptor (SSTR2)-selective somatostatin antagonists | The Salk Institute for Biological Studies (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110269683-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | UNIVERSITY HOSPITAL BASEL | 2011-11-03 | — | — | US | disclosed |
| EP-2383289-A1 | Receptor (SSTR2)-selective somatostatin antagonists | The Salk Institute for Biological Studies (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7960342-B2 | Side effect reduction; block receptor function so they can be used in therapy; labeled with radioactive iodine; drug screening | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2011-06-14 | — | — | US | disclosed |
| US-7192570-B2 | Compositions of somatostatin analogues | UNIVERSITY OF BERN (CH) | 2007-03-20 | — | — | US | disclosed |
| EP-1419178-B1 | SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE | UNIV BERN (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-7048907-B2 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | BIOPHYSICS ASSAY LABORATORY, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060067881-A1 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | BIOPHYSICS ASSAY LABORATORY, INC. | 2006-03-30 | — | — | US | disclosed |
| US-6911457-B2 | Imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions. | CARBOMER, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | UNIVERSITY OF BERN (CH) | 2004-12-02 | — | — | US | disclosed |
| US-20030207823-A1 | Novel diabetes imaging probes | CARBOMER, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030059368-A1 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | BIOPAL, INC. | 2003-03-27 | — | — | US | disclosed |
| EP-1283216-A1 | Somatostatin analogues binding to all somatostatin receptor subtypes and their use | Mallinckrodt Inc. (US) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | PLK4 3811/4885CCNC 3026/4885CDK8 1965/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | PLK4 3811/4885CCNC 3026/4885CDK8 1965/4885 |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | SSTR5, NPY5R, GLP1R | PLK4 3279/4885CCNC 4003/4885CDK8 3525/4885 |
| US-20110269683-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SSTR5, SSTR4, SSTR3 | PLK4 3598/4885CCNC 4255/4885CDK8 3572/4885 |
| US-20030207823-A1 | Novel diabetes imaging probes | IAPP, GPR119, DPP4 | PLK4 4191/4885CCNC 4625/4885CDK8 4609/4885 |
| US-20060067881-A1 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | ATP6V1B1, REN, GLS | PLK4 3732/4885CCNC 1526/4885CDK8 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.